Description
Qarziba is indicated for the treatment of high-risk neuroblastoma in patients aged 12 months and above, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and stem cell transplantation, as well as patients with history of relapsed or refractory neuroblastoma, with or without residual disease. Prior to the treatment of relapsed neuroblastoma, any actively progressing disease should be stabilised by other suitable measures.
Additional information
| Brand | Qarziba |
|---|---|
| Generic name | Dinutuximab beta for infusion |
| Form | Parenteral |
| Strength | 20mg/4.5ml |
| Manufacturer | Recordati S.p.A |
| Documents | Either PO or prescription |
| Storage | 2-8°C temperature |
| Global delivery time | 10-20 days |
| Pay attention | Shipment should be organized from our Company with airlines only (Not FedEx, DHL, EMS, Aramex, UPS), at the specified storage condition along with one data logger. |
Reviews
There are no reviews yet.